Kajian Pustaka Efektivitas dan Efek Samping Terapi Kombinasi Budesonide - Formoterol Fumarate pada Pasien Asma
Abstract
diberikan dalam bentuk inhalasi. Formoterol fumarate merupakan golongan obat agonis beta-2long actingyang bersifat bronkodilator setelah diberikan melalui inhalasi. Glukokortikoid(kostikosteroid) bekerja dengan menghambat respon pada jaringan yang mengalami prosesinflamasi, dikombinasikan denganLong-Acting ?2-Agonistyang merangsang reseptor adrenergipada paru-paru sehingga dapat merelaksasikan otot polos bronkus. Penelitian ini bertujuanuntuk melakukan kajianpustaka mengenai efektivitas terapi dan efek samping dari pemberian
terapi kombinasibudesonide-formoterol fumarate pada pasien asma.Proses pencarian artikeldilakukanmenggunakandatabasePubMeddan didapatkan 9 artikel yang sesuai dengan kriteria
inklusi dan eksklusi penelitian.Hasil penelitiandari 9 artikel tersebut menunjukkan bahwakombinasi budesonide200 ?gdan formoterol fumarate6 ?gyang digunakan 1 inhalasi 1-2 kalisehariefektifdalammengurangirisikoeksaserbasiparah,inflamasi,sertabaikuntukmengontrol gejala pada pasien dewasa dengan asma ringan sampai sedang yang dapat dilihatmelalui skor ACQ-5 dan FEV1sertaaman digunakan dalam pengobatan asmakecuali dalampenggunaanjangkapanjang(>48minggu)efeksampingyangdapatmunculsepertinasofaringitis (35%)daninfeksi saluran pernapasan atas (32%).
Save to Mendeley
Keywords
Full Text:
PDFReferences
Bateman.E.D., et al, 2018. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. The New England Journal of Medicine, 378(20): 1877-1887.
Bateman.E.D., et al, 2021. Positioning As-Needed Budesonide-Formoterol for Mild Asthma Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. Ann Am Thorac Soc, 18(12): 2007-2017.
Beasley.R., et al, 2019. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. The New England Journal of Medicine, 380(21): 2020-2030.
Brunton.L.L., Chabner.B.A., Knollmann.B.C. 2011. Goodman & Gilmans The Pharmalogical Basis of Therapeutics, 12th Edition. New York: The McGraw-Hills Companies.
Cheng.S., et al, 2020. Budesonide/Formoterol Anti-Inflamatory Reliever and Maintenance or Fluticasone Propionate/Salmeterol Plus As-needed, Short-Acting ?2 Agonist: Real-World Effectiveness in Patients without optimally Controlled asThma (REACT) Study. Drug Design, Development and Therapy, 2020(14): 5441-5450.
Chrastina.J. 2016. PICO(T) and PCD Formats of Clinically Relevant Question In The Conceptualization of Special Education Research. Journal of Exceptional, 1(8): 31-40.
Dipiro.J.T., Yee.G.C., Posey.L.M., Haines.S.T., Nolin.T.D., Ellingrod.V. 2020.
Pharmacotherapy: A Pathophysiologis Approach, 11th Edition. New York: The McGraw-Hills Companies.
FitzGerald.J.M., et al, 2021. Safety of As-Needed Budesonide-Mild Asthma: Data from the Two Phase III SYGMA Studies. Drug Safety, 44(2021): 467-478.
Garrard.J. 2017. Health Sciences Literature Review Made Easy The Matrix Method, 5th Edition. United States of America: Jones & Bartlett Learning.
Global Initiative for Asthma. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. 2020.
Global Initiative for Asthma. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. 2021.
Henderson.J., Hancock.K., Armour.C., Harrison.C., Miller.G. 2013. Asthma control in general practice-GP and patient perspectives compared. Australian Family Physician, 42(10):740-743
Hardy.J., et al, 2019. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL) a 52-week, open label, mulcentre, superiority, randomised controlled trial. Elsevier Ltd, http://dx.doi.org/10.1016/S0140-6736(19)31948-8.
Hochadel.M. 2014. Mosbys Drug Reference for Health Prosessions, 4th Edition. United States of America: Elsevier Mosby.
Kementerian Kesehatan Republik Indonesia, 2018. Hasil Utama RISKESDAS 2018, Indonesia.
Lacy.F.C., Amstrong.L.L., Goldman.M.P., Lance.L.L. 2009. Drug Informotion Handbook, 17th editon. American Pharmacists Association.
OByrne.P.M., et al, 2018. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. The New England Journal of Medicine, 378(20): 1865-1876.
OByrne.P.M., et al, 2020. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet respir Med, 9(2): 149-158.
Reddel.H.K., et al, 2021. Efficacy and Safety of As-Needed Budesonide-Formoterol in Adolescents with Mild Asthma. J Allergy Clin Immunol Pract, 9(8): 3069-3077.
Simbolon, D. 2021. Literature Review untuk Penelitian Kesehatan. Yogyakarta: Bintang Pustaka Madani.
Snyder, H. 2019. Literature Review as A Research Methodology: An Overview and Guidelines. Journal of Business Research, 104(2019): 333-339.
Straus, S.E., Glasziou, P., Richardson, W.S., Haynes, R.B. 2019. Evidence-Based Medicine: How To Practice and Teach EBM, 5th Edition. New York: Elsevier.
World Health Organization, 2019. Asthma. Diakses pada 23 Juli 2021,
https://www.who.int/news-room/fact-sheets/detail/asthma.
DOI: https://doi.org/10.33508/jfst.v10i1.4111